Edwards Lifesciences raised 2025 revenue forecast after Q1 results beat EPS estimates and TMTT sales jumped 58% amid strong global demand.
Latest Ratings for EW
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | UBS | Upgrades | Neutral | Buy |
| Jan 2022 | Morgan Stanley | Maintains | Overweight | |
| Jan 2022 | Raymond James | Maintains | Outperform |
